Stem Cell Club — Header Component
⏳ Standard price $2,499 → $1,999 locked in for life during our current promotion. Book now →

Research Spotlight · Crohn's Perianal Fistula

A stem cell product made for one painful Crohn's complication won approval in Europe in 2018. In 2024 it was pulled from the market. In 2026 the full trial data were finally published. Here is what happened, what the numbers say, and what it means for the whole field.

By The Stem Cell Club Editorial Team November 9, 2026 11 min read

Here is a story you rarely hear in the stem cell world. A product gets approved. Then a bigger, better trial runs. The product fails. And the company takes it off the market.

That is what happened to Alofisel (darvadstrocel), a stem cell therapy for complex perianal fistulas in people with Crohn's disease. It was an approved stem cell product in Europe. It is also a clean test of an old question: when a cell therapy looks good in a first trial, does it hold up in a larger one?

The full results of that larger trial, ADMIRE CD II, were published in Gastroenterology in 2026. This post walks through them. It also covers the smaller studies that are still going, and the new analyses that point in a different direction. No hype. Just the numbers.

Key takeaways Darvadstrocel is a product made of donor fat-derived mesenchymal stem cells, injected into the fistula tract during surgery. In ADMIRE-CD (2016, 212 patients, Phase 3), 50% of treated patients reached combined remission at week 24 versus 34% with placebo. In the larger ADMIRE CD II (568 patients, Phase 3), the result was 48.8% versus 46.3%, which was not a statistically significant difference. Safety looked similar in both groups. The EU withdrew the product at the end of 2024 because its benefit was no longer demonstrated. It was never approved by the FDA. Smaller studies of bone marrow cells and cell-derived vesicles are still reporting early signals, and a September 2026 network meta-analysis pooled seven MSC trials and reported higher fistula remission than placebo, but that pool leaves out ADMIRE CD II and carries high heterogeneity. The evidence is mixed. This is research, not a proven treatment.
568 patients in ADMIRE CD II, a Phase 3 placebo-controlled trial of darvadstrocel
48.8% vs 46.3% combined remission at week 24, cells versus placebo (P = .571). Not a significant difference
0 FDA approvals for darvadstrocel. The EU withdrew its approval in December 2024

What Is a Perianal Fistula, and Why Is Crohn's So Hard to Treat?

A perianal fistula is an abnormal tunnel between the inside of the lower bowel and the skin near the anus. In Crohn's disease, these tunnels can drain, hurt, form abscesses, and keep coming back.

They are common. In a population-based study of Crohn's patients in Olmsted County, Minnesota, published in Gastroenterology in 2002, the cumulative risk of a perianal fistula was 21% after 10 years and 26% after 20 years. Most fistulizing episodes in that study needed an operation.

Treatment usually combines surgery and medicine. Anti-TNF biologics are the long-standing medical cornerstone. But a 2026 review of the evidence noted that about 50% to 60% of patients do not get complete closure after the induction phase of anti-TNF therapy, and that relapse is common. That gap is why researchers went looking for something new.

Why Did Researchers Try Stem Cells for Crohn's Fistulas?

The logic is simple. Mesenchymal stem cells (MSCs) are thought to release signals that calm inflammation and help tissue repair. A fistula is a local problem: a stubborn, inflamed tunnel. So the idea was to put the cells right at the site instead of giving a drug to the whole body.

That is a hypothesis about how the cells might work, not a proven mechanism in these patients. Keep that in mind as we go through the trials.

What Did the First Trials Show?

Early small studies

One early randomized study from Leiden, in the Netherlands, tested donor bone marrow MSCs in 21 patients with refractory perianal fistulas. Patients got one of three cell doses or placebo. At week 12, healing was seen in 4 of 5 patients in the middle-dose group versus 2 of 6 on placebo. That difference did not reach statistical significance, and the higher dose group did worse than the middle one. No adverse events were linked to the injections. The study was too small to prove anything, but it made the next step worth taking.

ADMIRE-CD: the trial that led to approval

The key trial was ADMIRE-CD, a Phase 3, double-blind, placebo-controlled study across 49 hospitals in Europe and Israel, published in The Lancet in 2016. It enrolled 212 patients: 107 got a single injection of 120 million donor fat-derived MSCs (called Cx601 at the time), and 105 got saline.

The primary goal was combined remission at week 24. That means all treated external openings closed, and no fluid collection larger than 2 cm on a blinded MRI review. Results:

  • Intention-to-treat population: 50% (53 of 107) versus 34% (36 of 105), P = .024.
  • Modified intention-to-treat population: 51% (53 of 103) versus 36% (36 of 101), P = .021.
  • Treatment-related adverse events were 17% with cells and 29% with placebo.

A follow-up report in Gastroenterology in 2018 found that at week 52, combined remission was 56.3% with cells versus 38.6% with placebo. On this evidence, the European Medicines Agency authorized Alofisel in 2018.

One detail matters. The EMA's own account says that when it authorized the product, the benefit was considered modest, and the company was asked to provide results from a larger study. That larger study was ADMIRE CD II.

What Did ADMIRE CD II Find?

ADMIRE CD II (NCT03279081) was a Phase 3, randomized, double-blind, placebo-controlled trial run in Europe, Israel, and North America. It enrolled 568 adults with Crohn's disease and complex perianal fistulas who had not responded well enough to immune-suppressing drugs or biologics. A total of 283 got darvadstrocel and 285 got placebo. Both groups had the same surgical prep: curettage of the tract and closure of the internal opening.

The numbers, as published in Gastroenterology in 2026:

  • Primary goal, combined remission at week 24: 138 of 283 (48.8%) with darvadstrocel versus 132 of 285 (46.3%) with placebo. Estimated difference 2.4 percentage points, 95% CI −5.8 to 10.6, P = .571.
  • Key secondary goals: clinical remission at week 24 (P = .515) and time to clinical remission (P = .374). Neither showed a significant difference.
  • Safety: treatment-emergent adverse events in 73.0% with darvadstrocel and 73.4% with placebo. No new safety signals.

Read that again. The cell group did about the same in both trials: roughly half reached combined remission. What changed was the placebo group. In ADMIRE-CD, about a third of the placebo patients reached combined remission. In ADMIRE CD II, it was 46.3%.

Why? The paper does not settle that question, and we won't pretend to. One group of researchers writing in 2026 pointed to differences in patient selection and surgical management between the trials as a possible factor. Both arms in the second trial had curettage and closure of the internal opening, so surgical care itself may have helped a lot of patients in both groups. That is a hypothesis. It is worth holding loosely.

Takeda first announced that the trial missed its primary goal in October 2023. The full paper came out in 2026, and several of its authors are Takeda employees, which is worth knowing. A commentary in the same journal asked whether this is "the end of allogenic stem cell treatment for fistula patients." That tells you how seriously the field took it.

Why Was Alofisel Withdrawn From the EU Market?

In December 2024, the EMA announced that Alofisel was being withdrawn. Its statement said the benefit "is no longer demonstrated" and that it would not outweigh the risks associated with its use. The EMA noted that no new safety signals appeared in ADMIRE CD II. The issue was benefit, not new harm.

The agency said no new patients should be treated after December 13, 2024. Takeda, the company that marketed the product, said it could not provide additional data on effectiveness as the EMA expected, and chose to withdraw the product. It also said it was engaging health authorities in other countries where the product was approved.

What about the United States? Alofisel was never approved by the FDA. An NCBI Bookshelf review of orphan drug approvals lists it as approved in the EU in 2018 and not submitted to the FDA. So nothing was withdrawn here. It simply was never available.

If you want the plain-English version of how regulators decide what counts as an approved therapy, our guide to stem cell therapy and FDA approval covers it.

Does Any Evidence Still Support MSCs for Crohn's Fistulas?

Yes, some. It is mixed, and the quality varies. Here is how to read it.

A 2025 meta-analysis: 25 studies, 596 patients

A systematic review and meta-analysis in Stem Cell Research & Therapy (2025) pooled 25 prospective studies of MSC injections into Crohn's perianal fistulas. It searched the literature through December 2023, so it predates the full ADMIRE CD II paper. The pooled combined remission rate at 6 months was 57.9%. The authors concluded MSC-based therapies were effective, with no clear winner between fat-derived and bone marrow-derived cells. Note that it pooled studies of different designs, not only placebo-controlled trials.

A September 2026 network meta-analysis: 15 trials, 2,475 patients

A network meta-analysis in Frontiers in Immunology (published September 11, 2026) compared anti-TNF drugs and MSCs, each against placebo. It included 15 randomized trials: 7 of MSCs (412 patients) and 8 of biologics (2,063 patients). It reported higher fistula remission odds with MSCs than placebo (OR 5.33, 95% credible interval 2.19 to 19.03). Anti-TNF drugs also beat placebo (OR 2.19), and anti-TNF did better on clinical remission.

Three cautions the authors and a careful reader should weigh:

  • ADMIRE CD II is not in the MSC pool. The seven MSC trials listed in the paper's Table 1 do not include the 568-patient trial, even though the authors cite it in their discussion. The biggest MSC trial of all is missing from the pooled estimate.
  • Heterogeneity was high. The authors report an I² of 72.8% for MSC trials, which means the studies differed a lot in cell type, dose, and design. They wrote that the pooled estimate should not be read as a stable, reproducible effect for all MSC products.
  • The comparison is indirect. No trial has put MSCs head-to-head against anti-TNF drugs. The authors say their ranking cannot prove superiority.

Other small and early studies

A single-center Phase 1b/2a trial in the U.S. (published in Diseases of the Colon & Rectum in 2023) tested donor bone marrow MSCs in 23 patients, 18 treated and 5 controls. At 6 months, 83% of treated patients and 40% of controls had complete clinical and radiographic healing, with no adverse events related to the cells reported. It was single-blinded and tiny. Early signals like this are where trials such as ADMIRE-CD started, before the larger test.

Researchers are also studying products made from cells, not the cells themselves. A nonrandomized, single-center Phase 2 study (published in 2024, 23 enrolled, 20 completed) reported full tract closure in 12 patients (60%) after three injections of MSC-derived exosomes. And a randomized, placebo-controlled Phase 2a trial of an MSC-derived extracellular vesicle product (NCT06918808, estimated 36 patients) began recruiting in 2025, with primary completion estimated for mid-2027. Those are early. No results have been reported from the randomized trial.

How Do the Main Crohn's Fistula Cell Studies Compare?

Study Cells and delivery Design and size What it found
Leiden (2015) Donor bone marrow MSCs, injected into the fistula Randomized, double-blind, 21 patients, 3 doses plus placebo Middle dose 4 of 5 healed vs 2 of 6 on placebo at week 12; not significant
ADMIRE-CD (2016) Donor fat-derived MSCs (darvadstrocel), 120 million cells, injected into the fistula Phase 3, placebo-controlled, 212 patients Combined remission at week 24: 50% vs 34% (ITT, P = .024)
Lightner (2023) Donor bone marrow MSCs, injected into the fistula Phase 1b/2a, single-blinded, 23 patients (18 treated, 5 control) 83% vs 40% complete healing at 6 months; very small
ADMIRE CD II (2026) Donor fat-derived MSCs (darvadstrocel), 120 million cells, injected into the fistula Phase 3, placebo-controlled, 568 patients Combined remission at week 24: 48.8% vs 46.3% (P = .571); not significant
MSC exosome study (2024) MSC-derived exosomes, 3 injections into the fistula Phase 2, nonrandomized, no control group, 23 enrolled Full closure in 12 of 20 completers (60%); early signal only

What Can We Learn From This Story?

Three things stand out.

First, placebo-controlled trials matter. The cell group did about the same in both Phase 3 trials. The placebo group is what moved. Without a control group, a 48.8% remission rate would look like a success. With one, it looked like a tie. That is why single-arm studies, and clinic testimonials, can't tell you whether a treatment works.

Second, a first positive trial is not the end. ADMIRE-CD was a well-run randomized study, and it was positive. The second one wasn't. This pattern shows up across stem cell research. Our posts on lupus, stroke, and heart failure each tell a version of it.

Third, the field is honest enough to say so. The company reported the miss. Regulators acted. The journal published the result. That is how science is supposed to work, and it is the opposite of a sales pitch.

Not every MSC story ends this way. One cell product, Ryoncil, did win FDA approval, for a different condition, in children, based on a different kind of evidence. We cover it in our Ryoncil explainer. The lesson is not that cells never work. It is that each product and each condition has to earn its own evidence.

What Are the Honest Objections?

  • The biggest trial was negative. A 568-patient Phase 3 trial found no significant benefit. That belongs at the center of any summary.
  • Meta-analyses can mislead. The September 2026 network meta-analysis leaves out the largest MSC trial and mixes very different products and designs. A pooled number is not a guarantee.
  • The positive small studies are small. The 23-patient trials had few controls and one site each. Small studies often look better than the large trials that follow.
  • Surgery was part of the protocols. In the Phase 3 trials, patients had curettage and closure of the internal opening. A fistula trial tells you about the cells plus the operation, not the cells alone.
  • Trial products are not clinic products. Darvadstrocel was a specific, manufactured, expanded cell product injected into a surgically prepared tract. That is a different thing from anything offered in an elective clinic. Our overview of stem cell therapy side effects covers the general risks.

What Should Someone With Crohn's Fistulas Do With This Information?

We can't give medical advice, and we won't pretend to. But here is what the research itself points to.

Perianal Crohn's disease is a specialist problem. It is typically managed by a gastroenterologist and a colorectal surgeon working together, using medicines and surgical options with a track record. Nothing in these trials suggests replacing that care.

If you are curious about cell therapy for fistulas, the legitimate path is a registered clinical trial. You can search ClinicalTrials.gov for Crohn's perianal fistula cell studies and bring what you find to your care team. Real trials have a registration number, ethics approval, and usually a placebo or control group.

Be wary of anyone who quotes you a success rate for Crohn's fistulas, or who uses the old ADMIRE-CD numbers without mentioning ADMIRE CD II. The best available evidence does not support that kind of promise.

Where The Stem Cell Club Fits

We are not part of any of these studies and have no connection to Takeda, TiGenix, or the universities that ran them.

We offer umbilical cord Wharton's Jelly MSC options sourced from an FDA-registered U.S. lab. They are not darvadstrocel, which was made from donor fat tissue. They are not the bone marrow cells or vesicle products described above, and these results do not apply to them. Lab registration covers facility and manufacturing standards. It is not FDA approval of a therapy. Our offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease, including Crohn's disease or perianal fistulas, and we do not offer any fistula procedure or surgery.

If you have Crohn's disease, your gastroenterologist is the right first call. If you want an honest conversation about what regenerative research does and doesn't show, we're glad to have it. We keep a checklist of questions to ask any stem cell clinic, including us.

Frequently Asked Questions

Is there an approved stem cell therapy for Crohn's perianal fistulas?

Not anymore in Europe, and never in the United States. Darvadstrocel (Alofisel) was authorized in the EU in 2018, then withdrawn in December 2024 after the EMA said its benefit was no longer demonstrated. It was never approved by the FDA. Every cell therapy for Crohn's fistulas discussed here is now investigational.

What did the ADMIRE CD II trial find?

ADMIRE CD II was a Phase 3, placebo-controlled trial of 568 adults with Crohn's disease and complex perianal fistulas. Combined remission at week 24 was 48.8% with darvadstrocel and 46.3% with placebo (P = .571). Key secondary goals were also not significantly different, and adverse events were similar (73.0% vs 73.4%).

Why was Alofisel withdrawn from the EU market?

The European Medicines Agency said ADMIRE CD II failed to show that Alofisel was better than placebo, so its benefit was no longer demonstrated and would not outweigh its risks. No new safety signals were found. The company said it could not provide additional effectiveness data as the EMA expected and chose to withdraw. No new patients were to be treated after December 13, 2024.

Did the first trial, ADMIRE-CD, show a benefit?

Yes. ADMIRE-CD, a Phase 3 trial of 212 patients published in The Lancet in 2016, found combined remission at week 24 in 50% of treated patients versus 34% with placebo (intention-to-treat, P = .024). The EMA called the benefit modest and asked for a larger study. That larger study, ADMIRE CD II, did not confirm the result.

Do meta-analyses show stem cells work for Crohn's fistulas?

Some pooled analyses are favorable, but they have limits. A 2025 meta-analysis of 25 studies (596 patients) reported 57.9% combined remission at 6 months, and a September 2026 network meta-analysis of 15 randomized trials reported higher fistula remission than placebo. However, the 2026 analysis did not include ADMIRE CD II among its seven MSC trials, and its authors reported high heterogeneity and no direct comparison with anti-TNF drugs.

Are exosomes or cell-derived products being studied for Crohn's fistulas?

Yes, at an early stage. A nonrandomized, single-center Phase 2 study published in 2024 reported full closure in 12 of 20 patients who completed treatment with MSC-derived exosomes. A randomized, placebo-controlled Phase 2a trial of an MSC-derived extracellular vesicle product (NCT06918808, estimated 36 patients) is recruiting, with primary completion estimated for mid-2027.

How can I find a legitimate Crohn's fistula clinical trial?

Search ClinicalTrials.gov for perianal fistula and Crohn's disease studies and review what you find with your gastroenterologist or colorectal surgeon. Legitimate trials have a registration number, ethics approval, and usually a placebo or control group, and they rarely charge participants.

Does The Stem Cell Club offer stem cell therapy for Crohn's disease or fistulas?

No. The Stem Cell Club is not affiliated with any of the trials described here, and their results do not apply to our services. Our umbilical cord Wharton's Jelly MSC offerings are different products from those studied, we do not offer any fistula procedure, and our offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease, including Crohn's disease.

Want a Straight Answer About Regenerative Options?

Our free consultation is honest about what the research shows and what it doesn't. If something isn't a fit for you, we'll say so.

Schedule a Free Consultation → Or call (435) 281-2999

Educational content only, not medical advice. Individual results vary. Stem cell offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease. FDA registration of the source lab pertains to facility and manufacturing standards only and does not constitute FDA approval. This article discusses investigational and formerly approved products in published studies and registered clinical trials. The Stem Cell Club is not affiliated with these studies, and their findings do not apply to our services. If you have severe abdominal pain, fever, or heavy bleeding, seek urgent care. Talk with your doctor before starting or changing any treatment.

ADMIRE CD II: Colombel JF, Garcia Olmo D, Chen ST, et al. Darvadstrocel in patients with Crohn's disease with complex perianal fistulas: the ADMIRE CD II Phase 3 randomized trial. Gastroenterology. 2026;170:1562–1570. doi:10.1053/j.gastro.2025.12.033. PMID 41790076. NCT03279081.

Commentary: Buskens CJ, Bemelman WA. Interpreting a negative trial in complex perianal Crohn's disease: the end of allogenic stem cell treatment for fistula patients? Gastroenterology. 2026;170:1446–1447. doi:10.1053/j.gastro.2026.03.007. PMID 41850536.

ADMIRE-CD: Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281–1290. doi:10.1016/S0140-6736(16)31203-X. PMID 27477896. NCT01541579. Week-52 follow-up: Panés J, et al. Gastroenterology. 2018;154(5):1334–1342. doi:10.1053/j.gastro.2017.12.020. PMID 29277560.

Regulatory: European Medicines Agency, Alofisel withdrawn from the EU market, December 13, 2024. Takeda, Takeda update on Alofisel (darvadstrocel), December 13, 2024; Takeda, topline results of ADMIRE CD II, October 2023. NCBI Bookshelf, List of orphan approvals by FDA or EMA between 2018 and 2022.

Meta-analyses: Chen XM, Han LC, Han B, et al. Efficacy and safety of tumor necrosis factor-α inhibitors and mesenchymal stem cells in the treatment of fistulizing Crohn's disease: a systematic review and network meta-analysis. Front Immunol. 2026;17:1929235. doi:10.3389/fimmu.2026.1929235. PMID 42798531. Guillo L, Gravier Dumonceau R, Vélier M, et al. Efficacy of mesenchymal stem cell-based therapies in the treatment of perianal fistulizing Crohn's disease: a systematic review and meta-analysis. Stem Cell Res Ther. 2025;16:152. doi:10.1186/s13287-025-04272-y. PMID 40156066.

Smaller studies: Molendijk I, Bonsing BA, Roelofs H, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology. 2015;149:918–927. doi:10.1053/j.gastro.2015.06.014. PMID 26116801. Lightner AL, Reese J, Ream J, et al. A phase IB/IIA study of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of perianal fistulizing Crohn's disease. Dis Colon Rectum. 2023;66:1359–1372. doi:10.1097/DCR.0000000000002567. PMID 36602511. Hadizadeh A, Akbari Asbagh R, Heirani-Tabasi A, et al. Localized administration of mesenchymal stem cell-derived exosomes for the treatment of refractory perianal fistula in patients with Crohn's disease: a phase II clinical trial. Dis Colon Rectum. 2024;67:1564–1575. doi:10.1097/DCR.0000000000003502. PMID 39250316. NCT06918808 (Phase 2a, MSC-derived extracellular vesicles, recruiting).

Background: Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875–880. doi:10.1053/gast.2002.32362.